NACTN, a collaboration of university neurosurgical teams, is led by Robert Grossman, MD, a professor of neurosurgery at The Methodist Hospital Neurosurgical Institute in Houston.
The funding will support Phase 2 and 3 trials of the drug Riluzole, an FDA-approved neuroprotective drug. Riluzole is designed to limit spinal cord damage.
More Articles on Spine:
NASS Advocacy Documentary Calls for More Spine Specialist Involvement
2 Laser Spine Institute Studies on Lumbar Spinal Stenosis Treatments Published
6 Opportunities for Spine Surgeons to Forward the Field
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
